一年一度2023美国临床肿瘤学会（ASCO 2023）年会即将再次来临，此次会议已是59届，定于美国芝加哥当地时间2023年6月2日~6日举行。近日，ASCO官网公布了今年的摘要题目及作者信息。
2023 ASCO年会公布的泌尿肿瘤摘要专场的中国研究有8项，涵盖前列腺癌、膀胱癌和肾癌。【肿瘤资讯】特此整理，以飨读者。
前列腺癌
中国上海，复旦大学附属肿瘤医院 叶定伟教授
Abstract #5065
Poster Bd #159
Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.
HC-1119-04 III期试验：Deutenzalutamide（一种口服氘化雄激素受体抑制剂）vs安慰剂治疗阿比特龙+多西他赛治疗失败的mCRPC
中国上海，复旦大学附属肿瘤医院 朱耀教授
Abstract #5057
Poster Bd #151
Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with metastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.
ANGELA单中心前瞻性观察性试验：在接受阿比特龙的mCRPC患者中使用新型成像和液体活检进行肿瘤异质性和治疗应答评估
膀胱癌/尿路上皮癌
中国山东，山东省立医院 戴洪海教授
Abstract #4521
Poster Bd #13
Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.
KDR突变对膀胱癌患者使用免疫检查点抑制剂疗效的影响
中国北京，北京大学肿瘤医院 盛锡楠教授
Abstract #4543
Poster Bd #35
Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.
一项开放标签1b/2期研究：Disitamab vedotin（一种新型人源化抗HER 2抗体-药物偶联物（ADC））联合toripalimab治疗局部晚期或转移性尿路上皮癌
中国广东，中山大学孙逸仙纪念医院 林天歆教授
Abstract #4585
Poster Bd #77
Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.
替雷利珠单抗联合吉西他滨和顺铂新辅助治疗cT2-T4aN0M0膀胱尿路上皮癌患者的多中心临床研究最终分析结果
中国上海，复旦大学附属肿瘤医院 张海梁教授
Abstract #TPS4612
Poster Bd #98b
ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).
ALTER-UC-007：一项前瞻性、II期研究，比较安罗替尼+吉西他滨+顺铂与安罗替尼+派安普利单抗在肌层浸润性尿路上皮癌（MIUC）患者围手术期治疗效果
肾癌
中国广东，中山大学肿瘤防治中心 刘洋教授
Abstract #4533
Poster Bd #25
Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligometastatic renal cell carcinoma.
一项II期研究的初步结果：比较舒尼替尼单用或联合立体定向体部放疗（SBRT）治疗新诊断寡转移肾细胞癌
中国北京，中国医学科学院北京协和医学院 Cui honglei教授
Immunoglobulin as a predictive biomarker for the efficacy of immune checkpoint inhibitor combined with VEGF-TKI in metastatic renal cell carcinoma.
免疫球蛋白作为免疫检查点抑制剂联合 VEGF-TKI 治疗转移性肾细胞癌的疗效预测生物标志物
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions
排版编辑：肿瘤资讯-CY
苏公网安备 32059002004080号
